Announcements
- Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease
- Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)
- Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update
- Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102
- Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome
- Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting
- Ultragenyx to Participate at Investor Conferences in March
- Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
- Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2023 Financial Results and Corporate Update
More ▼
Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | 40.52 |
---|---|
High | 40.52 |
Low | 40.52 |
Bid | 40.32 |
Offer | 40.70 |
Previous close | 40.52 |
Average volume | -- |
---|---|
Shares outstanding | 82.34m |
Free float | 78.99m |
P/E (TTM) | -- |
Market cap | 3.50bn USD |
EPS (TTM) | -8.33 USD |
Data delayed at least 15 minutes, as of Sep 27 2022.
More ▼